Meeting
2013 ASCO Annual Meeting
NRAS mutation: A potential biomarker of clinical response to immune-based therapies in metastatic melanoma (MM).
Authors
Douglas Buckner Johnson
Vanderbilt-Ingram Cancer Center, Nashville, TN
Douglas Buckner Johnson , Christine Marie Lovly , Marisa Flavin , Gregory Dan Ayers , Zhiguo Zhao , Wade Thomas Iams , Anthony John Iafrate , Elizabeth Gates Berry , Charles R Terry , Ryan J. Sullivan , Richard D. Carvajal , Jeffrey Alan Sosman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Citation
J Clin Oncol 31, 2013 (suppl; abstr 9019)
DOI
10.1200/jco.2013.31.15_suppl.9019
Abstract #
9019
Poster Bd #
7
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
CA045-001: A phase III, randomized, open label study of bempegaldesleukin (NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients (pts) with previously untreated, unresectable or metastatic melanoma (MEL).
First Author: Nikhil I. Khushalani
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Immunomodulation of pembrolizumab (pembro) treated metastatic melanoma patients (pts) after progression with sequential temozolomide (TMZ): A case series.
First Author: Umang Swami
Poster
2014 ASCO Annual Meeting
The Memorial Sloan Kettering Cancer Center (MSKCC) experience of systemic therapy in mucosal melanoma.
First Author: Christiana Bitas
Poster
2023 ASCO Annual Meeting
Association of ultra-sensitive ctDNA assay to identify actionable variants and response to immune checkpoint inhibitor (ICI) therapy in metastatic melanoma.
First Author: Christoffer Gebhardt